Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 37INDUSTRY 36NIH 8NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Refractory Differentiated Thyroid Gland Carcinoma 1Pancreatic Neoplasms 1Melanoma 1Glioma 1Brain Neoplasms 1

Interventions

Interferon-alpha 6Radiosurgery 4Dacarbazine 4encorafenib 3binimetinib 3aldesleukin 3Immunohistochemistry 3Gene Expression Profiling 3Filgrastim 3Cisplatin 3Vinblastine 2Temozolomide 2Radiotherapy 2Polymerase Chain Reaction 2Nivolumab 2Ipilimumab 2Immunologic Techniques 2Flow Cytometry 2trametinib 1sulforaphane 1sargramostim 1romidepsin 1perifosine 1pembrolizumab 1peginterferon alfa-2b 1montanide ISA 51 1lorukafusp alfa 1incomplete Freund's adjuvant 1dipeptidase 1 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Melanoma × trametinib × Clear all
NCT02974803 2021-08-20

Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

Canadian Cancer Trials Group

Phase 2 Terminated
6 enrolled 3 charts
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡